Host-microbe single-cell sequencing — the simultaneous profiling of human and microbial transcriptomes from infected tissues, enabling pathogen-specific host response characterization, representing 12% of single-cell applications and growing 35% annually — creates the most commercially dynamic market segment, with the Single Cell Sequencing Market reflecting microbiome-host interaction as the premium growth commercial driver.

The COVID-19 lung single-cell atlas — the identification of ACE2-expressing epithelial subtypes, interferon-responsive macrophage states, and viral RNA-containing cells through scRNA-seq of 100,000+ cells from infected lungs — demonstrates the infectious disease application. The Human Cell Atlas and COVID-19 Cell Atlas consortiums validating scRNA-seq for pathogen tropism and immune response mapping illustrate the research scale, with 50+ pathogen-specific single-cell atlases now published.

Intracellular pathogen detection — the simultaneous capture of host and bacterial/fungal transcripts from infected single cells — creates the mechanistic insight application. 10x Genomics' multi-species scRNA-seq detecting Mycobacterium tuberculosis transcripts within individual macrophages demonstrates the technical capability, with pharmaceutical companies using host-pathogen single-cell profiling to identify druggable host factors for broad-spectrum antivirals.

Gut microbiome-host crosstalk — the single-cell analysis of intestinal epithelial cells responding to specific bacterial species or metabolites — creates the commensal interaction application. Research identifying segmented filamentous bacteria-induced Th17 differentiation and Clostridioides difficile toxin-mediated epithelial damage at single-cell resolution demonstrates the precision, with probiotic and live biotherapeutic companies incorporating scRNA-seq into strain selection and mechanism validation.

Do you think host-pathogen single-cell sequencing will replace traditional infection models, or will it complement in vivo and in vitro systems for comprehensive mechanistic understanding?

What pathogens have been studied using single-cell sequencing? Pathogen atlas: viruses (SARS-CoV-2: lung, nasal, immune cell tropism; HIV: latent reservoir identification; influenza: airway epithelial response; HBV/HCV: hepatocyte infection; CMV: immune evasion mechanisms); bacteria (Mycobacterium tuberculosis: macrophage infection, granuloma heterogeneity; Salmonella: epithelial invasion; Listeria: intracellular life cycle; Pseudomonas: biofilm-host interaction; Staphylococcus: immune evasion); fungi (Candida albicans: epithelial interaction; Aspergillus: lung infection; Cryptococcus: CNS tropism); parasites (Plasmodium: liver stage, blood stage; Toxoplasma: CNS infection; Leishmania: macrophage infection); technical approaches (scRNA-seq of infected tissue, pathogen RNA capture, dual-species alignment, host response deconvolution, pathogen heterogeneity within host cells).

How is single-cell sequencing used for antimicrobial drug discovery? Drug discovery applications: target identification (host dependency factors — druggable genes required for pathogen replication; pathogen virulence factors — essential for infection); mechanism of action (transcriptional response to drug treatment, on-target vs. off-target effects, resistance mechanisms); combination therapy (synergistic drug pairs identified through transcriptomic response profiling); host-directed therapy (immunomodulatory targets, interferon response enhancement, inflammation resolution); resistance prediction (single-cell identification of persister cells, pre-existing resistant subpopulations, adaptive resistance trajectories); clinical translation (patient stratification based on host response signature, pharmacodynamic biomarkers, companion diagnostics); platform integration (scRNA-seq with CRISPR screens, high-content imaging, metabolomics, proteomics); throughput (10,000-100,000 cells per experiment, 100-500 compounds screened, 3-6 month target-to-validation timeline).